AI assistant
EXELIXIS, INC. — Director's Dealing 2017
Mar 4, 2017
30561_dirs_2017-03-03_af97c53c-0b1e-4e12-8fdc-d4a0d9f75dd5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EXELIXIS, INC. (EXEL)
CIK: 0000939767
Period of Report: 2017-03-01
Reporting Person: Lamb Peter (EVP, Scientific Strategy & CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-03-01 | Common Stock | M | 20000 | $7.18 | Acquired | 93600 | Direct |
| 2017-03-01 | Common Stock | M | 25000 | $7.51 | Acquired | 118600 | Direct |
| 2017-03-01 | Common Stock | S | 45000 | $22.19 | Disposed | 73600 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-03-01 | Option (right to buy) | $7.18 | M | 20000 | Disposed | 2019-12-08 | Common Stock (20000.0) | Direct |
| 2017-03-01 | Option (right to buy) | $7.51 | M | 25000 | Disposed | 2019-12-14 | Common Stock (25000.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 16128 | Indirect |
Footnotes
F1: Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 27, 2016.
F3: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.76 to $22.59. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents 16,128 shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of March 1, 2017.
F5: The option, representing the right to purchase a total of 75,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 9, 2013.
F6: The option, representing the right to purchase a total of 25,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 15, 2013.